BRCA1 and ovarian cancer: Strickland and coworkers demonstrated that a higher neoantigen load in the BRCA1/2-mutated ovarian cancers compared to HR-proficient tumors translates to a significantly higher number of CD3+ TILs compared to HR-proficient tumors.